Ascorbic Acid (AA) with neoadjuvant chemotherapy. Participants received an initial loading dose of 1,5 g Ascorbic Acid (i.v in 100 ml sterile water) on Day 1 followed by 0,75g Ascorbic Acid (i.v in 100 ml sterile water) on Day 2-4 at each chemotherapy cycle and concomitant neoadjuvant chemotherapy regimens administered at the choice of treating physician.
Ascorbic Acid is administered intravenously before neoadjuvant therapy in D1

Placebos (normal saline (0.9%) with neoadjuvant chemotherapy. 100 ml normal saline 0.9% (placebo) will be administered (i.v) by the same scheme as Ascorbic Acid on Day 1 and respectively Day 2-4 at each chemotherapy cycle.
Concomitant neoadjuvant chemotherapy regimens administered at the choice of treating physician.

Breast Cancer

1,5 g ascorbic acid dissolved in 100 ml sterile water, and 0,75 g ascorbic acid dissolved in 100 ml sterile water.

Ascorbic Acid

Placebos

Academic Emergency County Hospital Sibiu

Intravenous Ascorbic Acid Supplementation in Neoadjuvant Chemotherapy for Breast Cancer

Phase I/II Randomized Study to Evaluate the Role of Intravenous Ascorbic Acid Supplementation to Conventional Neoadjuvant Chemotherapy in Women With Breast Cancer

Assessments are made through analysis of reported incidence of treatment-emergent Adverse Events. Toxicities (AEs) in both groups will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03

The symptom checklist and the symptom related measures as defined by European Organization for Research and Treatment of Cancer (Questionnaire C30 and BR23) will be compared between arms using frequency tables

Therapeutic efficacy assessed by Pathological response. Percentage of Participants Achieving Complete Response (CR) According to the Residual Cancer Burden score.

Objective Response Rate using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Guidelines

Assessment of laboratory parameters including interleukin (IL)-6 and vascular endothelial growth factor (VEGF).

Pop Catalin Florin, MD

Principal Investigator

CHU-UCL Namur (site Mont-Godinne), Belgium

75 mg of 3,3´-diindolylmethane (DIM) once a day for 30 days

Two pills of BioResponse DIM® 150 are equal to 75 mg of DIM pure

DIM pills

Placebo pills, proportionate by the same provider, vials and pills were the same size, shape and material containing the DIM pills

Placebo Pill

Association of Market Research Agencies and Public Opinion 2005

Effectiveness of DIM Supplements to Increase 2-OHE1/16 Ratio

Effectiveness of DIM Supplements to Increase 2-OHE1/16 Ratio in Premenopausal Mexican Women With Risk of Breast Cancer

A schedule was provided to the patients to record the daily intake of the supplement DIM/placebo

A schedule was provided to the patients to record daily the presence of side effects that have been reported in other studies such as diarrhea, nausea , vomiting , headache and flatulence.

First pregnancy after 35 years or no living children

Have at least one first-degree or second degree family, who has had or have the disease

According to the committee of socioeconomic levels of the Mexican Association of Market Research Agencies and Public Opinion (AMAI)

Number of portions per day (1 cup raw or 1/2 cup cooked) of any cruciferous vegetables

Estela Ytelina Godínez Martínez

Researcher in Medical Sciences B

Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes

Women randomized to this study arm will receive intravenous ascorbic acid (50g in 500 ml sterile water) prior to their odd-numbered chemotherapy cycles. During the even-numbered chemotherapy cycles, these subjects will receive intravenous normal saline (0.9%).

Women randomized to this study arm will receive intravenous ascorbic acid (50g in 500 ml sterile water) prior to their even-numbered chemotherapy cycles. During the odd-numbered chemotherapy cycles, these subjects will receive intravenous normal saline (0.9%).

Fatigue

500 g ascorbic acid dissolved in 500 ml sterile water.

Normal Saline

Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer

Prospective Double Blind Study of the Effect of Intravenous High Dose Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer

Patients will complete the validated questionnaire Fatigue Symptom Inventory (FSI)

ascorbic acid/rintasyöpä

Intravenous Ascorbic Acid Supplementation in Neoadjuvant Chemotherapy for Breast Cancer

Effectiveness of DIM Supplements to Increase 2-OHE1/16 Ratio

Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer

Täydellisin lääketieteellinen tietokanta tieteen tukemana